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Targeted scVEGF/177Lu radiopharmaceutical
inhibits growth of metastases and can be
effectively combined with chemotherapy
Mary Rusckowski1, Yuzhen Wang, Francis G. Blankenberg2, Zoia Levashova2,3, Marina V. Backer4
and Joseph M. Backer4*
Abstract
Background: scVEGF/177Lu is a novel radiopharmaceutical targeted by recombinant single-chain (sc) derivative of
vascular endothelial growth factor (VEGF) that binds to and is internalized by vascular endothelial growth factor
receptors (VEGFR). scVEGF/177Lu potential as adjuvant and neoadjuvant anti-angiogenic therapy was assessed in
metastatic and orthotopic mouse models of triple-negative breast cancer.
Methods: Metastatic lesions in Balb/c mice were established by intracardiac injection of luciferase-expressing
4T1luc mouse breast carcinoma cells. Mice with metastatic lesions received single intravenous (i.v.) injection of
well-tolerated dose of scVEGF/177Lu (7.4 MBq/mouse) at day 8 after 4T1luc cell injection. Primary orthotopic breast
tumors in immunodeficient mice were established by injecting luciferase-expressing MDA231luc human breast
carcinoma cells into mammary fat pad. Tumor-bearing mice were treated with single injections of scVEGF/177Lu
(7.4 MBq/mouse, i.v), or liposomal doxorubicin (Doxil, 1 mg doxorubicin per kg, i.v.), or with a combination of Doxil
and scVEGF/177Lu given at the same doses, but two hours apart. “Cold” scVEGF-targeting conjugate was included in
controls and in Doxil alone group. The effects of treatments were defined by bioluminescent imaging (BLI),
computed tomography (CT), computed microtomography (microCT), measurements of primary tumor growth, and
immunohistochemical analysis.
Results: In metastatic model, adjuvant treatment with scVEGF/177Lu decreased overall metastatic burden and
improved survival. In orthotopic primary tumor model, a combination of Doxil and scVEGF/177Lu was more efficient
in tumor growth inhibition than each treatment alone. scVEGF/177Lu treatment decreased immunostaining for
VEGFR-1, VEGFR-2, and pro-tumorigenic M2-type macrophage marker CD206.
Conclusions: Selective targeting of VEGFR with well-tolerated doses of scVEGF/177Lu is effective in metastatic and
primary breast cancer models and can be combined with chemotherapy. As high level of VEGFR expression is a
common feature in a variety of cancers, targeted delivery of 177Lu for specific receptor-mediated uptake warrants
further exploration.
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Background
Targeting VEGF signaling via VEGF receptors in tumor
vasculature has become a well-established treatment
modality, known as anti-angiogenic therapy [1–5]. Sev-
eral major anti-angiogenic drugs are already in the clinic,
and a multitude of clinical trials for various cancers are
in progress [1]. Unfortunately, these inhibitors are, at
best, only marginally effective and, in many cases, are
not effective at all, as was recently underscored by the
failures in phase III breast cancer clinical trials [6]. The
current explanation for this ineffectiveness is that
VEGF/VEGFR inhibitors induce only a transient regres-
sion of tumor vasculature followed by vascular rebound
that rekindles aggressive tumor growth [7–9]. Two
mechanisms are, apparently, involved in vascular re-
bound: (1) so-called evasive resistance of endothelial
cells, which allows them to use pathways other than
VEGF/VEGFR for growth and survival, and (2) only re-
cently appreciated systemic pro-angiogenic/pro-inflam-
matory/pro-tumorigenic host responses induced by
inhibition of VEGF/VEGFR signaling in VEGFR-positive
cell populations, including endothelial, immune, pro-
genitor, and stem cells [10–21].
With the goal of enhancing the efficacy of anti-
angiogenic therapy, we are developing a novel radiophar-
maceutical that is designed for VEGFR-mediated intra-
cellular delivery of 177Lu [22]. We reasoned that since
such a radiopharmaceutical is not an inhibitor of VEGFR
signaling, it would not lead to either evasive resistance
of endothelial cells or to systemic responses associated
with inhibition of this pathway in various host cells. On
the other hand, we expected that VEGFR-mediated
intracellular 177Lu accumulation would lead to a dose-
dependent radiotoxicity, which would be more pro-
nounced in VEGFR-overexpressing tumor endothelial
cells relative to the cells with physiologically normal
levels of VEGFR. Critically, particularly high levels of
VEGFRs are found in tumor endothelial cells that are
positioned at the tips of growing angiogenic vascular
sprouts [23], making them the primary targets for
scVEGF/177Lu.
To enable VEGFR-mediated delivery, we employed
scVEGF-PEG-DOTA targeting conjugate, which is a de-
rivative of human VEGF-A re-engineered into a single-
chain polypeptide format (scVEGF), and site-specifically
derivatized with PEGylated DOTA chelator [24]. Like
parental VEGF-A, various site-specific scVEGF conju-
gates, including radiolabeled scVEGF-PEG-DOTA conju-
gates, bind to VEGFRs with high affinity and undergo
VEGFR-mediated internalization [22, 24].
We initially tested 177Lu-radiolabeled scVEGF-PEG-
DOTA (scVEGF/177Lu) in an orthotopic triple-negative
breast cancer model in syngeneic and immunocom-
promised mice [22]. We focused on breast cancer
because current anti-angiogenic drugs are particularly
inefficient for this disease [6]. Biodistribution, radiotoxi-
city, dosimetry, and dose-dependence studies established
a safe and well-tolerated dose for a single i.v. injection of
scVEGF/177Lu that led to significant tumor growth in-
hibition [22], with tumor uptake (2.32 + 0.14 %ID/g)
similar to that for PET and SPECT tracers based on
scVEGF-PEG-DOTA conjugate [24]. The most remark-
able outcome of single scVEGF/177Lu injection was a
long-term sustainable vascular regression and, particu-
larly, the decline in the prevalence of VEGFR-2 overex-
pressing cells in tumor vasculature; the effects were only
transient in mice treated with conventional anti-
angiogenic VEGF/VEGFR inhibitors, bevacizumab, or
sunitinib [22]. Interestingly, combining scVEGF/177Lu
with these anti-angiogenic drugs affected only a subset
of mice, increasing the fraction of mice with slow grow-
ing tumors [22]. These findings indicated that scVEGF/
177Lu might be a more effective drug than the current
inhibitors of VEGFR signaling and stimulated a further
exploration of scVEGF/177Lu in more realistic models of
disease and treatment.
In this study, we explored a possibility of incorporating
scVEGF/177Lu into current therapy for breast cancer,
considering both adjuvant and neoadjuvant settings. The
majority of breast cancer patients undergo adjuvant
therapy, because local and distant recurrent disease is
frequent, with metastatic dissemination being the main
cause of mortality. As a relevant model for adjuvant
therapy, we selected an aggressive and highly metastatic
4T1 murine breast carcinoma grown in immunocompe-
tent Balb/c mice. We report here that single well-
tolerated dose of scVEGF/177Lu is effective in inhibiting
metastatic growth of 4T1luc in Balb/c mice that war-
rants a further development of this radiopharmaceutical
as a stand-alone or combination adjuvant therapy to pre-
vent metastatic dissemination in post-surgery breast can-
cer patients.
Improving the outcome of neoadjuvant therapy is an
unmet clinical need, which is particularly important for
triple-negative breast cancer (TNBC) patients because of
so-called triple-negative paradox [25]. TNBC patients
have higher rates of pathological complete response to
neoadjuvant therapy than patients with other breast
tumor types. However, those who do not respond have a
significantly worse prognosis [25]. Thus, improving neo-
adjuvant therapy with timely incorporation of scVEGF/
177Lu treatment may have a significant clinical impact.
We report here that scVEGF/177Lu can be efficiently
combined with doxorubicin chemotherapy, a standard
front-line chemotherapeutic for breast cancer, in a
model of orthotopic human MDA231luc xenograft, sug-
gesting a potential application as a neoadjuvant combin-
ation therapy for breast cancer.
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Methods
Cells and reagents
MDA231luc cells are derivatives of MDA-MB-231 hu-
man breast cancer cells engineered to stably express fire-
fly luciferase [24]. 4T1luc cells are derivatives of 4T1
mouse mammary tumor cells engineered to stably ex-
press firefly luciferase [24]. Both cell lines were cultured
in Dulbecco’s modified Eagle medium (DMEM) media
(Gibco) with non-essential amino acids, 10 % fetal bo-
vine serum, and 1 % penicillin/streptomycin at 37 °C in
a humidified atmosphere with 5 % CO2. Lutetium-177
chloride was from PerkinElmer Life Sciences Inc. (Bos-
ton, MA). The liposomal formulation of doxorubicin
(Doxil) was from Janssen Products, LP (Horsham, PA).
scVEGF-PEG-DOTA was produced at SibTech, as de-
scribed [24]. All other chemicals were analytical grade
from standard suppliers.
Synthesis of scVEGF-PEG-DOTA
Preparation of scVEGF-PEG-DOTA conjugate followed
[24] included some modifications of the published
protocol [24]. We first conjugated 3.4 kDa bifunctional
maleimide-PEG-amine to NHS-DOTA chelator via NHS
chemistry, as opposed to using maleimide-PEG-NHS
and DOTA-Bz-amine described in [24], and then site-
specifically conjugating maleimide-PEG-DOTA to thiol
group in Cys-tag of scVEGF via maleimide chemistry.
Radiolabeling scVEGF-PEG-DOTA with 177Lu
Radiolabeling was performed as described [22] with
minor modifications. Briefly, 177LuCl3 in 0.05 M HCl
(about 480 MBq, 9 μl) was added to 0.1 M sodium acet-
ate (40 μl), pH 5.5, for a final pH of 5.0, transferred to
scVEGF-PEG-DOTA (150 μg, 70 μl) in 0.1 M sodium
acetate, pH 5.5, and heated at 55 °C for 1 h. The labeling
reaction was loaded on a PD-10 column equilibrated
with 0.1 % BSA in phosphate-buffered saline (PBS) and
scVEGF/177Lu fractions were collected. Labeling effi-
ciency and radiochemical purity was determined by
TLC on Whatman No. 1 paper with saturated sodium
chloride as solvent, a system where scVEGF/177Lu is
retain at start, while free 177Lu has Rf > 0.6. Radiola-
beled conjugate was also characterized by HPLC on a
Superose™ 12 10/300 column eluted with 0.6 mL/min
80 % 0.1 M Tris-HCl, pH 8.0 and 20 % acetonitrile,
where scVEGF/177Lu is eluted at ~13 min, while free 177Lu
is eluted 25–29 min. The labeling efficiency by HPLC was
about 80–85 %, and by TLC was 99 %, and specific activity
was in the range of 2.2–2.4 MBq/μg.
Animal experiments
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Massachusetts Medical School (Worcester, MA) and
Stanford University (Palo Alto, CA). Female BALB/c
and SCID mice (Charles River Laboratories International,
Inc., Wilmington, MA), weighing 17 to 22 g, about 4–
6 weeks old, were fed standard mouse chow and water,
and housed under standard conditions.
To establish metastatic breast cancer model, Balb/c
mice were inoculated with 4T1luc cells via intracardiac
injection. 4T1luc cells were grown to 70–80 % of conflu-
ence in T-75 flasks, treated with ×1 trypsin/EDTA,
washed, and suspended in Dulbecco’s phosphate-
buffered saline (DPBS) at 5 × 105 per milliliter. The cells
were kept on ice and delivery was completed within 1 h
after harvesting. Animals were anesthetized with isoflur-
ane and placed on a sterile drape with limbs secured and
chest swabbed with 70 % ethanol. A 0.3-cm3 syringe
(29G needle) containing 5 × 104 4T1luc cells in 0.1 ml
DPBS was inserted slowly into the chest in the second
intercostal space directly into the left ventricle. Proper
placement in the left ventricle was indicated by blood
flow into the syringe, and the cells were delivered slowly
(approximately 30 s for 0.1 ml). Once complete, the nee-
dle was withdrawn by pulling straight out quickly, and
the animal was placed on a heating pad and monitored
until awake and ambulatory.
To establish MDA231luc orthotopic breast cancer
model, immunodeficient SCID mice were inoculated
with MDA231luc cells into mammary fat pads.
MDA231luc cells were grown to 90 % of confluence in
T-75 flasks, treated with ×1 trypsin/EDTA, washed, and
suspended in cold serum-free DMEM at 80 × 106 cells
per milliliter. The cells were kept on ice, and delivery
was completed within 1 h of harvest. For inoculation,
the animals were anesthetized with isoflurane and cells
were resuspended by gentle pipetting before drawing
50 μl (4 × 106 cells) into a 0.5-ml syringe (28G needle).
The needle with bevel up was inserted into the fourth
mammary fat pad, and cells delivered slowly. The same
was repeated on the opposite side, resulting in two tu-
mors per mouse. After injection, the mice were kept se-
dated on a heating pad for about 40 min.
Monitoring and treatment of 4T1luc metastatic lesions
4T1luc spread and growth were monitored by whole
body bioluminescent imaging (BLI) in ventral and dorsal
positions. BLI was acquired on an IVIS 100 (PerkinEl-
mer) with exposure of 60 s about 12–15 min after intra-
peritoneal luciferin injection (PerkinElmer, Waltham,
MA), at dose of 150 mg/kg of body weight. Whole body
bioluminescence was measured by Living Image 4.1 soft-
ware using a sum of both dorsal and ventral views. Bone
lesions were documented with microtomography
(microCT). Baseline scans were acquired prior to cell deliv-
ery on day 0 and then on day 4 and at 2–3 day intervals
thereafter. The CT was acquired on a small animal
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NanoSPECT/CT with 65 kVp voltage and 500 ms exposure
time, and the CT reconstructions were with InVivoScope
1.43 software (Bioscan, Washington, DC). Bone metastasis
was also confirmed on the final day by high-resolution
microCT on a SCANCO vivaCT 75 microCT with
20.5 μm scan resolution (Scanco USA, Inc., Wayne, PA).
On day 8 after cell inoculation, ten mice with leg bone
metastasis confirmed by BLI received scVEGF/177Lu
(5–6 μg protein/mouse, 7.4 MBq/mouse) in 50 μl via
retro-orbital sinus injection. Seven mice received
equivalent amounts of unlabeled scVEGF-PEG-DOTA
conjugate as control. On days 15–17, the animals were
euthanized; leg bones and visceral metastases were
harvested for analysis.
Treatment of MDA231 orthotopic tumors
Following MDA231luc cells inoculation, mice were ob-
served daily and tumors were measured by calipers
every 2–3 days. Tumor volume was calculated as V =
0.5*(L*W*H), where L is the long axis, W is the short
axis, and H is the height of a tumor.
When the tumors reached 50–200 mm3, about 2–3 weeks
after tumor cell inoculation, animals were randomized into
four treatment groups: (1) unlabeled scVEGF-PEG-DOTA,
(n = 20); (2) scVEGF/177Lu (7.4 MBq/mouse, n = 10); (3)
Doxil plus unlabeled scVEGF-PEG-DOTA, (n = 9); and (4)
Doxil plus scVEGF/177Lu (7.4 MBq/mouse, n = 15).
scVEGF/177Lu or scVEGF-PEG-DOTA (5–6 μg/mouse)
were delivered in 50 μl via retro-orbital sinus injection and
a single dose of Doxil (1 mg/kg body weight) was delivered
in 100 μl via tail vein injection.
Animals were euthanized between 7 and 14 days after
treatment. Tumors were harvested and snap-frozen in
OCT for immunohistochemical analysis (IHC).
IHC
Bone samples from both hind legs in the 4T1luc meta-
static model were fixed in 10 % formalin for 48 h, rinsed
in PBS, decalcified in 14 % EDTA solution for 10–14
days, and embedded in paraffin. To unmask biomarkers,
5-μm sections were de-waxed and incubated in 10 mM
sodium citrate pH 6, 0.05 % Tween-20 at 95 °C for
30 min. Double fluorescent staining with tyramine ampli-
fication technique was done as described in details re-
cently [26], with the following primary antibodies. For
formalin-fixed tissue, VEGFR-2-specific (Cell Signaling
#2479BC), VEGFR-1-specific (Abcam C-terminal-specific
#Ab2350), and CD31-specific (DiaNova #DIA-310-M); for
snap-frozen primary tumors and visceral metastases,
CD31-specific and VEGFR-2-specific antibodies (BD Phar-
mingen #550274 and #550549) and CD206-specific anti-
body (Serotek #1111) were used. Slides were mounted in
medium for fluorescence with DAPI for nuclear counter-
staining (Vector Laboratories) and observed in Zeiss
Axiovert microscope. For quantitative analyses of im-
munofluorescent staining, digital images of multiple
microscopic fields were obtained under identical condi-
tions, and the percentage of pixels containing antigen-
specific staining above the same threshold for a selected
region of interest was determined by histogram analysis
using Zeiss software.
Results
Single injection of scVEGF/177Lu inhibits growth of
metastases
To explore scVEGF/177Lu in adjuvant settings, we used
a mouse model with metastatic lesions but without pri-
mary tumor. Intracardiac injection of 4T1luc cells in
Balb/c resulted in rapid appearance of visceral and bone
metastases that were readily detectable by BLI, CT, and
microCT (Fig. 1a–c and Additional file 1: Figure S1 and
Additional file 2: Figure S2) and confirmed by H&E
staining of harvested tissue and bones (not shown). To
assess effects of scVEGF/177Lu on progression of metasta-
ses, at day 8 after tumor cell inoculation, mice in treat-
ment group (n = 11) received single injection of previously
Fig. 1 Growth of 4T1luc mouse breast carcinoma metastatic lesions in syngeneic Balb/c mice. a Representative longitudinal whole body BLI
performed during 13 days after intracardiac injection of 4T1luc cells. Prior to imaging mice received lucefirin (0.5 mg/mouse, intraperitonially).
b Representative CT imaging of metastatic bone lesions at day 13 after 4T1luc injection. Blue arrows indicate metastatic lesions. Red cross marks
left hind leg. c MicroCT image of right and left hind leg knee. Areas of significant pitting and large areas of osteolysis associated with bone
metastatic lesions are visible around knee joints
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established [22] well-tolerated dose of scVEGF/177Lu
(7.4 MBq/mouse) via retro-orbital sinus. To avoid poten-
tial confounding effects, control mice (n = 11) received the
equivalent amounts of “cold,” unlabeled scVEGF-PEG-
DOTA conjugate. Kaplan-Meier survival analysis indicated
that scVEGF/177Lu-treated mice survived significantly bet-
ter than control mice (Fig. 2a), with difference character-
ized by chi-squared statistics of 9.02 (p < 0.0015) and
hazard ratio of 5.73 (5.15 to 6.31 for 95 % confidence
interval).
In order to further assess the development of meta-
static burden in individual mice, we performed longitu-
dinal whole body BLI in each control and treated mouse.
Since BLI after luciferine injection was due only to
luciferase-expressing tumor cells, we reasoned that
quantitative BLI might provide a useful comparison be-
tween treated and control mice. Indeed, longitudinal BLI
changes in individual mice were readily approximated as
exponential (R2 > 0.9) in all but one mouse in treated
group and one mouse in control group, which allowed
for calculation of BLI “doubling time” as a surrogate par-
ameter for changes in metastatic burden. The calculated
doubling time was found to be significantly longer (1.44 ±
0.48 vs. 0.97 ± 0.17 day, p = 0.04) for treated vs. control
mice (Fig. 2b), indicating that a slower growth of meta-
static burden is, most likely, responsible for the delayed
mortality in scVEGF/177Lu-treated mice (Fig. 2a).
Immunofluorescent analysis of harvested visceral
metastatic lesions shows that VEGFR-2 colocalized
well with a pan-endothelial marker CD31, indicating
that VEGFR-2 is predominantly expressed on tumor
endothelium (Fig. 3a, for a kidney metastatic lesion). In
contrast, in the same visceral metastases, VEGFR-1
only occasionally colocalized with CD31 (not shown)
or VEGFR-2 (Fig. 3b), indicating that VEGFR-1 is pre-
dominantly expressed on non-endothelial cells.
In bone metastases, VEGFR-1 was more widespread
than VEGFR-2, and both receptors mostly did not
colocalize with each other or with CD31, indicating that
both VEGFRs are predominantly expressed on non-
endothelial cells (Fig. 4a–c for control and Fig. 4d–f for
scVEGF/177Lu-treated mice). Although VEGFR-1 immu-
nostaining was highly heterogeneous, it appears that the
prevalence of VEGFR-1 in bone metastatic lesions was
decreased in scVEGF/177Lu-treated mice, relative to con-
trol (compare Fig. 4a, d).
Combining scVEGF/177Lu with chemotherapy
To explore scVEGF/177Lu in neoadjuvant settings, we
employed immunodeficient mouse model with orthoto-
pic human breast MDA231luc xenografts [22, 24]. For
combination therapy, we used a single injection of clin-
ical grade doxorubicin-loaded liposomes, Doxil. We rea-
soned that liposomes could remain entrapped in tumor
after scVEGF/177Lu-induced vascular regression, while
free drug would have a more limited access and/or
cleared faster from tumor tissue. To account for poten-
tial effects of scVEGF moiety in scVEGF/177Lu-treated
groups, both control groups (no treatment and Doxil
alone) received the equivalent doses of “cold” scVEGF-
PEG-DOTA conjugate.
For quantitative analysis of tumor growth, it was ap-
proximated as exponential and tumor volume doubling
times were determined for individual tumors. We found
a significant diversity in the rates of tumor growth in
each group (Fig. 5) and even between the rates of tumor
growth in the right and left mammary fat pad in the
same mouse (not shown). However, for mice treated
with combination therapy, the average doubling time
was significantly longer than that for mice treated with
either scVEGF/177Lu (p < 0.0003) or Doxil (p < 0.0001)
alone. Of note, scVEGF/177Lu or a combination of
scVEGF/177Lu with Doxil caused similar regression of
tumor vasculature, as judged by VEGFR-2 prevalence on
tumor cryosections, while Doxil alone did not cause any
vascular regression (Additional file 3: Figure S3).
Fig. 2 Single injection of scVEGF/177Lu at day 8 after 4T1luc inoculation delays metastases-induced mortality and inhibits metastatic growth.
Control mice received equivalent amounts of cold scVEGF-PEG-DOTA. a Kaplan-Meier analysis of survival in control (blue) and treated (red) mice.
b Doubling time values for longitudinal increase in bioluminescent intensity of total metastatic burden for individual control (blue) and treated
(red) mice. Average and p values are indicated
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scVEGF/177Lu treatment decreases CD206+ M2-type
macrophages
The effects of scVEGF/177Lu treatment on the prevalence
of pro-tumorigenic M2-type tumor-associated macro-
phages (TAM) were assessed by CD206 immunostaining.
Although CD206 prevalence was highly heterogeneous,
we found that scVEGF/177Lu induced a decrease in aver-
age CD206 prevalence in tumor tissue in MDA231luc pri-
mary tumor model. This effect was detectable as early as
on day 1 after treatment and was sustained at least until
day 15 (Fig. 6a, b). Interestingly, this rapid CD206 decline
was similar to that observed for VEGFR-2 prevalence in
treated mice (Additional file 4: Figure S4). We also
observed a scVEGF/177Lu-induced decline in CD206
prevalence in kidney metastatic lesions in 4T1luc meta-
static model (Additional file 5: Figure S5).
Discussion
Since both innate and adaptive immunity critically affect
responses to anti-cancer therapy [27–29], we explored
effects of adjuvant treatment with scVEGF/177Lu in im-
munocompetent mice without primary tumor but with
established 4T1luc metastatic lesions (Fig. 1, Additional
file 1: Figure S1 and Additional file 2: Figure S2), which
typically kill mice after 12–14 days. We found (Fig. 2)
that a single injection of a safe dose of scVEGF/177Lu re-
sulted in rather dramatic decrease in mortality on this
time scale with hazard ratio of 5.73 (5.15 to 6.31 for
Fig. 3 In kidney metastatic lesions, VEGFR-2 is expressed predominantly on CD31+ endothelial cells, while more abundant VEGFR-1 is predominantly
expressed on non-endothelial cells. a Colocalization of immunofluorescent staining for CD31 (green) and VEGFR-2 (red). b VEGFR-1 (green) and VEGFR-2
(red) are expressed mostly on non-overlapping subsets of cells. Nuclei stained with DAPI (blue). ×40 objective
Fig. 4 In bone metastatic lesions, VEGFR-1 and VEGFR-2 are expressed on non-overlapping subsets of non-endothelial cells. Top panels, Control
group. Bottom panels, scVEGF/177Lu treated group. a, d Lack of colocalization between VEGFR-1 and CD31. b, e Lack of colocalization between
VEGFR-2 and CD31. c, f Lack of colocalization between VEGFR-1 and VEGFR-2. Nuclei stained with DAPI (blue). ×40 objective
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95 % confidence interval). A slower growth of metastatic
lesions in scVEGF/177Lu-treated animals, as assessed by
the whole animal BLI, further supports the effectiveness
of scVEGF/177Lu treatment.
In exploring the putative scVEGF/177Lu targets,
VEGFR-1 and VEGFR-2, we found that VEGFR-2 preva-
lence was significantly higher than that of VEGFR-1 in
visceral metastases, but the opposite was true for bone
metastases (Figs. 3 and 4). Furthermore, in visceral
metastases, only VEGFR-2 receptors were expressed pre-
dominantly on endothelial cells, as judged by colocaliza-
tion with a pan-endothelial marker CD31 (Fig. 3), while
in bone metastases, both VEGFR-1 and VEGFR-2 were
largely expressed on different non-endothelial cells
(Fig. 4).
Recent studies in tumor models and human tumors
indicate that, apart from their role in tumor endothelial
cells, VEGF receptors may be intimately involved in
tumor cell physiology, including “stemness” of tumor
cells [30, 31]. VEGFR-2 expression was reported in
4T1cells [32], while VEGFR-1 is expressed on several
types of tumor cells, both in vitro and in vivo [21], in-
cluding at least 16 human breast carcinoma cell lines
[33, 34], and it is particularly prominent in osteosarcoma
bone lesions [35]. Moreover, in a large patient cohort,
VEGFR-1 expression by cancer cells in tumor biopsies
was correlated with negative prognosis [36]. Our finding
of widespread VEGFR-1 expression on tumor cells in
bone lesions suggests that VEGFR-1 could be a promin-
ent target for scVEGF/177Lu in this type of breast cancer
Fig. 5 Combining scVEGF/177Lu with Doxil inhibits tumor growth more efficiently than single-agent treatment in orthotopic MDA231luc human
breast carcinoma model in SCID mice. Effects of scVEGF/177Lu+Doxil, scVEGF/177Lu alone or Doxil (+ equivalent amounts of cold scVEGF-PEG-DOTA),
relative to control tumors injected with equivalent amounts of cold scVEGF-PEG-DOTA conjugate alone. Growth curves for individual tumors were
approximated as exponential and tumor doubling time was calculated for each tumor and the sets of data presented as watershed plots for each
group. Average doubling time ±STD is indicated on the plot for each group
Fig. 6 scVEGF/177Lu induces a decrease in CD206 immunostaining in primary orthotopic MDA231luc tumors. Images of CD206 immunostaining
were captured with ×5 objective. Waterfall plots for CD206 prevalence in individual microscopic fields on immunostained cryosections for control
and scVEGF/177Lu-treated MDA231luc tumor-bearing mice at day 1 (a) and day 15 (b) after treatment. For each group, cryosections were prepared
from four tumors harvested from two mice
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lesions. It is also tempting to speculate that a radiophar-
maceutical based on a VEGFR-1 specific mutant of
scVEGF might provide additional advantages in targeting
VEGFR-1-positive tumor cells in metastatic lesions, and
we are currently testing this hypothesis.
Since developing scVEGF/177Lu as a part of combination
therapy would be a more realistic translational approach,
we combined it with liposomal formulation of doxorubicin
(Doxil), a standard front-line chemotherapeutic for breast
cancer, for treatment of orthotopic MDA231luc tumors.
In regimens selected for monotherapy, either Doxil or
scVEGF/177Lu inhibited tumor growth approximately two-
fold. However, a near simultaneous (only 2 h apart) treat-
ment with both drugs effectively blocked tumor growth
(Fig. 5). This is in contrast with previously tested combina-
tions of scVEGF/177Lu with anti-angiogenic drugs, bevaci-
zumab or sunitinib, which affected growth of MDA231luc
tumors only in a subset of mice [22]. Taking together, our
data indicate that combining scVEGF/177Lu low doses of
front-line chemotherapy might have a higher therapeutic
potential than combination with anti-angiogenic drugs.
Originally, anti-angiogenic drugs were expected to work
through tumor starvation caused by vascular regression
[1–6]; however, more recently systemic pro-angiogenic/
pro-inflammatory/pro-tumorigenic host responses in-
duced by these drugs are being taken into consideration
as well [10–21]. One of the culprits in these responses are
tumor-associated macrophages (TAMs), which are the
major component of tumor stroma in invasive breast car-
cinomas and their enhanced accumulation is associated
with poor prognosis [37, 38]. TAMs are predominantly of
pro-angiogenic, anti-inflammatory, and immunosuppres-
sive M2-type macrophages that are characterized by the
production of cytokines supporting these activities [39, 40].
Typically, treatment with either anti-cancer chemothera-
peutics or anti-angiogenic drugs increases the prevalence
of M2-type TAMs, which blunts the response to chemo-
therapy through several mechanisms [39, 40]. Surprisingly,
although treatment with scVEGF/177Lu is clearly anti-
angiogenic, unlike other anti-angiogenic drugs, it ap-
pears to decrease the prevalence of CD206-positive
M2-type TAMs in primary tumor (Fig. 6) and meta-
static lesions in the kidney (Additional file 4: Figure
S4). We are currently exploring whether this effect is
due to scVEGF/177Lu-induced systemic changes or to
specific alterations in tumor vasculature.
Conclusions
We have demonstrated that targeting VEGF receptors
with a single well-tolerated dose of a novel radiopharma-
ceutical, scVEGF/177Lu, delays mortality and inhibits
growth of metastatic lesions initiated by intracardiac injec-
tion of mouse breast carcinoma cells in immunocompetent
mice. A single injection of scVEGF/177Lu in combination
with a low-dose Doxil blocks tumor growth in an ortho-
topic human breast carcinoma model. In addition to de-
pleting tumor vasculature of VEGFR-2 overexpressing
cells, scVEGF/177Lu induced a sustainable decrease in
tumor prevalence of pro-tumorigenic/pro-angiogenic
M2-type macrophages. Taken together, these findings
support further development of targeted scVEGF/177Lu
radiopharmaceutical.
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Additional file 1: Figure S1. Representative image of mouse with
4T1luc bone metastatic lesions. CT and high resolution MicroCT of bone
lesion areas show significant pitting and large areas of osteolysis.
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Additional file 2: Figure S2. Enlarged high resolution MicroCT images
of shoulder area from Additional file 1: Figure S1. MicroCT shows
significant pitting and large areas of osteolysis around joints. (PDF 46 kb)
Additional file 3: Figure S3. Treatment effects on VEGFR-2 prevalence
in tumor. Images of VEGFR-2 immunostaining were captured with 5x
objective. For each group, VEGFR-2 prevalence was calculated for 13-14
microscopic fields on immunostained cryosections prepared from tumors
harvested from 2-3 mice. (PDF 90 kb)
Additional file 4: Figure S4. Rapid declining in VEGFR-2 prevalence in
response to scVEGF/177 Lu treatment. The difference relative to control
was statistically significant (p=0.0001) from Day 1. No statistically significant
difference between VEGFR-2 prevalence at days 3 to 15 after treatment. The
number of analyzed microscopic fields (N) on cryosections from different
mouse tumors (n) for each time point was as following: N/n: Control – 19/4,
D1 – 28/6, D3 – 24/5, D5 – 25/6, D8 – 32/6, D11 – 27/6, D15 – 27/6.
(PDF 69 kb)
Additional file 5: Figure S5. Immunostaining for VEGFR-2 (red) and
CD206 (green) on cryosections of 4T1luc kidney metastatic lesions from
control (A) and scVEGF/177 Lu treated (B) Balb/c mice. 40x objective.
(PDF 80 kb)
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